<DOC>
	<DOCNO>NCT02605044</DOCNO>
	<brief_summary>The objective compare efficacy safety masitinib combination FOLFIRI ( irinotecan , 5-fluorouracil folinic acid ) placebo combination FOLFIRI second line treatment patient .</brief_summary>
	<brief_title>Study Compare Efficacy Safety Masitinib Combination With FOLFIRI Placebo Combination With FOLFIRI Second Line Treatment Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patient nonresectable metastatic colorectal cancer Metastatic disease amenable surgical resection Patient second line treatment progression accord RECIST criterion Patient measurable lesion accord RECIST criterion ( version 1.1 ) Patient eligible standard second line treatment FOLFIRI Patient ECOG ≤ 2 Patient adequate organ function Patient life expectancy &gt; 3 month Female male patient ≥ 18 Patient weight &gt; 40 kg BMI &gt; 18 Patient receive FOLFIRI More 1 prior chemotherapy regimens metastatic colorectal cancer Pregnant , intent pregnant , nurse female patient Patient chronic inflammatory bowel disease Patient treat cancer colorectal cancer within five year enrollment Patient hepatic involvement &gt; 50 % Patient active central nervous system ( CNS ) metastasis history CNS metastases Patient active infection Patient present cardiac disorder Any previous treatment investigational agent chemotherapy biological agent within four week prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>